Company: CDT
Filing Date: 2025-07-31
Form Type: S-3
Source: 0001641172-25-021729
Chunk: 16

Company: CDT Equity Inc.
Filing Date: 2025-07-31
Form: S-3
Chunk 16
---
 any sale or disposition of shares of Common Stock held by the Selling Stockholders pursuant to this prospectus.

<div align='center'>SELLING STOCKHOLDERS</div>

This prospectus covers the resale or other disposition by the Selling Stockholders identified in the table below of up to an aggregate 255,285 shares of our Common Stock issued pursuant to the Joint Development Agreement, Consulting Agreement, and the issuance to E3 Fund SP. The Selling Stockholders acquired their securities in the transactions described above under the heading “ Joint Development Agreement” and “Harold Eytan Consulting Agreement”, and “ E3 Fund SP”.

The table below sets forth, as of July 29, 2025, the following information regarding the Selling Stockholders:

| ● | the                                                                                                                                     
 name of the Selling Stockholders;                                                                                                       |
| ● | the                                                                                                                                     
 number of shares of Common Stock owned by the Selling Stockholders prior to this offering;                                              |
| ● | the                                                                                                                                     
 number of shares of Common Stock to be offered by the Selling Stockholders in this offering;                                            |
| ● | the                                                                                                                                     
 number of shares of Common Stock to be owned by the Selling Stockholders assuming the sale of all of the shares of Common Stock covered 
 by this prospectus; and                                                                                                                 |
| ● | the                                                                                                                                     
 percentage of our issued and outstanding shares of Common Stock to be owned by Selling Stockholders assuming the sale of all of the     
 shares of Common Stock covered by this prospectus based on the number of shares of Common Stock issued and outstanding as of July       
 29, 2025.                                                                                                                               |

Except as described above, the number of shares of Common Stock beneficially owned by the Selling Stockholders has been determined in accordance with Rule 13d-3 under the Exchange Act and includes, for such purpose, shares of Common Stock that the Selling Stockholder has the right to acquire within 60 days of July 29, 2025.

All information with respect to the Common Stock ownership of the Selling Stockholders has been furnished by or on behalf of the Selling Stockholders. We believe, based on information supplied by the Selling Stockholders, that except as may otherwise be indicated in the footnotes to the table below, the Selling Stockholders have sole voting and dispositive power with respect to the shares of Common Stock reported as beneficially owned by the Selling Stockholders. Because the Selling Stockholders identified in the table may sell some or all of the shares of Common Stock beneficially owned by them and covered by this prospectus